 Brian Greffe
Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Ewing | 3 | 2025 | 103 | 0.430 |
Why?
| | Kidney Neoplasms | 4 | 2021 | 413 | 0.370 |
Why?
| | Hepatoblastoma | 4 | 2022 | 52 | 0.360 |
Why?
| | Cisplatin | 3 | 2025 | 345 | 0.260 |
Why?
| | Liver Neoplasms | 4 | 2022 | 776 | 0.240 |
Why?
| | Bone Neoplasms | 2 | 2025 | 259 | 0.240 |
Why?
| | Testicular Neoplasms | 2 | 2017 | 111 | 0.220 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 66 | 0.220 |
Why?
| | Rhabdomyosarcoma | 2 | 2019 | 65 | 0.220 |
Why?
| | Clonal Evolution | 1 | 2025 | 47 | 0.210 |
Why?
| | Wilms Tumor | 2 | 2018 | 89 | 0.200 |
Why?
| | Granuloma, Plasma Cell | 1 | 2003 | 12 | 0.200 |
Why?
| | Dexamethasone | 1 | 2025 | 365 | 0.190 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2214 | 0.170 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 362 | 0.170 |
Why?
| | Hearing Loss | 1 | 2025 | 249 | 0.170 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.170 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 83 | 0.170 |
Why?
| | Neoplasms | 4 | 2025 | 2906 | 0.170 |
Why?
| | Eye Neoplasms | 1 | 2021 | 30 | 0.160 |
Why?
| | Ribonuclease III | 1 | 2021 | 43 | 0.160 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 46 | 0.160 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1321 | 0.160 |
Why?
| | DEAD-box RNA Helicases | 1 | 2021 | 83 | 0.160 |
Why?
| | Child | 25 | 2025 | 22707 | 0.160 |
Why?
| | Protein C | 2 | 1989 | 54 | 0.150 |
Why?
| | Adolescent | 25 | 2025 | 22529 | 0.150 |
Why?
| | Child, Preschool | 16 | 2025 | 11853 | 0.140 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2016 | 76 | 0.140 |
Why?
| | Hodgkin Disease | 2 | 2016 | 171 | 0.140 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2022 | 372 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2021 | 441 | 0.130 |
Why?
| | Cytodiagnosis | 1 | 2017 | 31 | 0.130 |
Why?
| | Frozen Sections | 1 | 2017 | 24 | 0.120 |
Why?
| | Head and Neck Neoplasms | 2 | 2021 | 561 | 0.120 |
Why?
| | Seminoma | 1 | 2017 | 20 | 0.120 |
Why?
| | Survivors | 5 | 2016 | 523 | 0.120 |
Why?
| | Lung Diseases | 1 | 2003 | 780 | 0.120 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 177 | 0.120 |
Why?
| | Nuclear Proteins | 1 | 2021 | 740 | 0.110 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 641 | 0.110 |
Why?
| | Health Planning | 1 | 2015 | 47 | 0.110 |
Why?
| | Osteosarcoma | 2 | 2007 | 82 | 0.110 |
Why?
| | Abdomen, Acute | 1 | 1994 | 21 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2022 | 826 | 0.110 |
Why?
| | Prognosis | 5 | 2025 | 4316 | 0.100 |
Why?
| | Male | 29 | 2025 | 72842 | 0.100 |
Why?
| | Infant | 13 | 2025 | 10077 | 0.100 |
Why?
| | Transition to Adult Care | 1 | 2015 | 103 | 0.100 |
Why?
| | Heart Diseases | 2 | 2016 | 341 | 0.100 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2013 | 22 | 0.100 |
Why?
| | Survival Rate | 5 | 2019 | 2090 | 0.090 |
Why?
| | Ambulatory Care Facilities | 1 | 2015 | 269 | 0.090 |
Why?
| | Sarcoma | 1 | 2015 | 207 | 0.090 |
Why?
| | Humans | 39 | 2025 | 145474 | 0.090 |
Why?
| | Gene Rearrangement | 1 | 2013 | 155 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2013 | 167 | 0.090 |
Why?
| | Bone Marrow Transplantation | 3 | 2008 | 298 | 0.090 |
Why?
| | Denys-Drash Syndrome | 1 | 2011 | 4 | 0.090 |
Why?
| | Embolectomy | 1 | 2011 | 13 | 0.090 |
Why?
| | Female | 27 | 2025 | 78844 | 0.080 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2013 | 231 | 0.080 |
Why?
| | Tumor Lysis Syndrome | 1 | 2010 | 10 | 0.080 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2664 | 0.080 |
Why?
| | Mutation | 1 | 2021 | 4075 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2010 | 1963 | 0.070 |
Why?
| | Pulmonary Embolism | 1 | 2011 | 241 | 0.070 |
Why?
| | Lymphoma, B-Cell | 1 | 2010 | 140 | 0.070 |
Why?
| | Risk Assessment | 3 | 2015 | 3747 | 0.070 |
Why?
| | SEER Program | 3 | 2016 | 229 | 0.070 |
Why?
| | Brain Neoplasms | 4 | 1999 | 1329 | 0.070 |
Why?
| | Leiomyosarcoma | 2 | 1998 | 29 | 0.070 |
Why?
| | Receptors, Erythropoietin | 1 | 2007 | 21 | 0.070 |
Why?
| | Topotecan | 1 | 2007 | 17 | 0.060 |
Why?
| | Fetal Blood | 1 | 1989 | 327 | 0.060 |
Why?
| | Retrospective Studies | 9 | 2022 | 17291 | 0.060 |
Why?
| | Translocation, Genetic | 2 | 2021 | 119 | 0.060 |
Why?
| | Young Adult | 6 | 2025 | 14218 | 0.060 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2007 | 75 | 0.060 |
Why?
| | Survival Analysis | 3 | 2018 | 1374 | 0.060 |
Why?
| | Paraneoplastic Syndromes, Nervous System | 1 | 2006 | 14 | 0.060 |
Why?
| | Carboplatin | 1 | 2006 | 162 | 0.060 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 212 | 0.060 |
Why?
| | Leukemia | 1 | 2008 | 246 | 0.060 |
Why?
| | Neuroblastoma | 2 | 2006 | 174 | 0.060 |
Why?
| | Injection, Intratympanic | 1 | 2025 | 2 | 0.060 |
Why?
| | Age Factors | 3 | 2018 | 3342 | 0.060 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2006 | 100 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2011 | 1127 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2025 | 5423 | 0.050 |
Why?
| | Gels | 1 | 2025 | 85 | 0.050 |
Why?
| | Neoplasms, Second Primary | 1 | 2006 | 102 | 0.050 |
Why?
| | Primary Health Care | 1 | 2015 | 1735 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2008 | 480 | 0.050 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 81 | 0.050 |
Why?
| | Adult | 14 | 2019 | 40777 | 0.050 |
Why?
| | Immunologic Factors | 1 | 2006 | 260 | 0.050 |
Why?
| | Disease-Free Survival | 2 | 2019 | 767 | 0.050 |
Why?
| | Abdominal Abscess | 1 | 2003 | 26 | 0.050 |
Why?
| | Stem Cells | 1 | 2008 | 628 | 0.050 |
Why?
| | Incidence | 3 | 2007 | 2923 | 0.050 |
Why?
| | Databases, Factual | 3 | 2018 | 1490 | 0.050 |
Why?
| | Pulmonary Veno-Occlusive Disease | 1 | 2003 | 10 | 0.050 |
Why?
| | Spinal Neoplasms | 1 | 2003 | 37 | 0.050 |
Why?
| | Combined Modality Therapy | 3 | 2021 | 1266 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 442 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 688 | 0.040 |
Why?
| | Recurrence | 2 | 2003 | 1138 | 0.040 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 30 | 0.040 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 31 | 0.040 |
Why?
| | Kidney Diseases, Cystic | 1 | 2021 | 24 | 0.040 |
Why?
| | Antibodies, Monoclonal | 2 | 2006 | 1505 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 734 | 0.040 |
Why?
| | Pneumothorax | 1 | 2021 | 52 | 0.040 |
Why?
| | Infant, Newborn | 4 | 2016 | 6447 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2025 | 1111 | 0.040 |
Why?
| | Thyroid Diseases | 1 | 2000 | 44 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 381 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2021 | 176 | 0.040 |
Why?
| | Radiotherapy | 1 | 2021 | 204 | 0.040 |
Why?
| | Molecular Weight | 2 | 1989 | 312 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1443 | 0.040 |
Why?
| | Smooth Muscle Tumor | 1 | 1998 | 6 | 0.030 |
Why?
| | Skull Neoplasms | 1 | 1998 | 21 | 0.030 |
Why?
| | Sarcoma, Synovial | 1 | 1998 | 20 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1767 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2021 | 1041 | 0.030 |
Why?
| | Vincristine | 2 | 2010 | 142 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 465 | 0.030 |
Why?
| | Leiomyoma | 1 | 1998 | 61 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1471 | 0.030 |
Why?
| | Fluorouracil | 2 | 2010 | 231 | 0.030 |
Why?
| | Common Variable Immunodeficiency | 1 | 1997 | 26 | 0.030 |
Why?
| | Intraoperative Period | 1 | 2017 | 69 | 0.030 |
Why?
| | Polymyositis | 1 | 1996 | 13 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2016 | 69 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1149 | 0.030 |
Why?
| | Neutropenia | 1 | 1995 | 154 | 0.030 |
Why?
| | Organizational Innovation | 1 | 2015 | 119 | 0.030 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 1994 | 21 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2769 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2015 | 200 | 0.030 |
Why?
| | Time Factors | 3 | 2018 | 7123 | 0.030 |
Why?
| | Fever | 1 | 1995 | 319 | 0.030 |
Why?
| | Laparotomy | 1 | 1994 | 113 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 1996 | 279 | 0.030 |
Why?
| | Klinefelter Syndrome | 1 | 1995 | 69 | 0.020 |
Why?
| | Flow Cytometry | 2 | 2008 | 1162 | 0.020 |
Why?
| | Health Status | 1 | 1999 | 832 | 0.020 |
Why?
| | Immunohistochemistry | 2 | 2013 | 1716 | 0.020 |
Why?
| | Program Development | 1 | 2015 | 368 | 0.020 |
Why?
| | Emergencies | 1 | 1994 | 174 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3413 | 0.020 |
Why?
| | Middle Aged | 7 | 2017 | 36215 | 0.020 |
Why?
| | Physical Examination | 1 | 1994 | 243 | 0.020 |
Why?
| | Transcription Factors | 1 | 2021 | 1734 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 1994 | 202 | 0.020 |
Why?
| | Chronic Disease | 2 | 2015 | 1808 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2134 | 0.020 |
Why?
| | Aged | 4 | 2022 | 26153 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2015 | 1300 | 0.020 |
Why?
| | Appendicitis | 1 | 1994 | 150 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 325 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2378 | 0.020 |
Why?
| | Radiography | 1 | 1994 | 852 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2865 | 0.020 |
Why?
| | United States | 3 | 2017 | 16098 | 0.020 |
Why?
| | Disease Management | 1 | 2015 | 653 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 943 | 0.020 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2010 | 34 | 0.020 |
Why?
| | Hyperuricemia | 1 | 2010 | 47 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2010 | 105 | 0.020 |
Why?
| | Hyperkalemia | 1 | 2010 | 36 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 244 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1371 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2007 | 210 | 0.020 |
Why?
| | Herpesvirus 4, Human | 2 | 1998 | 172 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 95 | 0.010 |
Why?
| | Urogenital Neoplasms | 1 | 2006 | 5 | 0.010 |
Why?
| | Respiratory Insufficiency | 1 | 2010 | 326 | 0.010 |
Why?
| | Cerebrospinal Fluid | 1 | 2006 | 88 | 0.010 |
Why?
| | Behavior | 1 | 2006 | 89 | 0.010 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2006 | 90 | 0.010 |
Why?
| | Anti-Bacterial Agents | 2 | 1995 | 1923 | 0.010 |
Why?
| | Thrombosis | 1 | 1989 | 400 | 0.010 |
Why?
| | Rituximab | 1 | 2006 | 210 | 0.010 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2006 | 73 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4553 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2006 | 423 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 2010 | 713 | 0.010 |
Why?
| | Hemorrhage | 1 | 2010 | 822 | 0.010 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2010 | 699 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 8333 | 0.010 |
Why?
| | RNA, Viral | 2 | 1998 | 692 | 0.010 |
Why?
| | Survival | 1 | 2003 | 38 | 0.010 |
Why?
| | Stereotaxic Techniques | 1 | 2003 | 42 | 0.010 |
Why?
| | Thoracic Vertebrae | 1 | 2003 | 82 | 0.010 |
Why?
| | Morbidity | 1 | 2003 | 322 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2003 | 300 | 0.010 |
Why?
| | Motor Activity | 1 | 2006 | 718 | 0.010 |
Why?
| | Immunotherapy | 1 | 2006 | 666 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2006 | 870 | 0.010 |
Why?
| | Hyperthyroidism | 1 | 2000 | 22 | 0.010 |
Why?
| | Hypothyroidism | 1 | 2000 | 67 | 0.010 |
Why?
| | Thyroid Nodule | 1 | 2000 | 57 | 0.010 |
Why?
| | Sleep | 1 | 2006 | 888 | 0.010 |
Why?
| | Sella Turcica | 1 | 1998 | 17 | 0.010 |
Why?
| | Health Status Indicators | 1 | 1999 | 167 | 0.010 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 51 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1998 | 68 | 0.010 |
Why?
| | Fatal Outcome | 1 | 1998 | 305 | 0.010 |
Why?
| | Herpesviridae Infections | 1 | 1998 | 148 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1997 | 318 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 1997 | 414 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 237 | 0.010 |
Why?
| | Thyroid Neoplasms | 1 | 2000 | 350 | 0.010 |
Why?
| | Prednisone | 1 | 1996 | 224 | 0.010 |
Why?
| | Pineal Gland | 1 | 1995 | 15 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1995 | 316 | 0.010 |
Why?
| | Anesthesia, Dental | 1 | 1974 | 21 | 0.010 |
Why?
| | Tooth Extraction | 1 | 1974 | 28 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 2 | 1998 | 3904 | 0.010 |
Why?
| | Anesthesia, General | 1 | 1974 | 120 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 1996 | 477 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 1996 | 1508 | 0.010 |
Why?
| | Quality of Life | 1 | 2003 | 3204 | 0.010 |
Why?
| | Neutrophils | 1 | 1995 | 1124 | 0.000 |
Why?
| | Cohort Studies | 1 | 2000 | 6013 | 0.000 |
Why?
| | Treatment Outcome | 1 | 2003 | 11772 | 0.000 |
Why?
| | Surveys and Questionnaires | 1 | 1999 | 6066 | 0.000 |
Why?
| | Prospective Studies | 1 | 1995 | 8057 | 0.000 |
Why?
| | Risk Factors | 1 | 1995 | 10885 | 0.000 |
Why?
| | Oral Hemorrhage | 1 | 1974 | 3 | 0.000 |
Why?
| | Tachycardia | 1 | 1974 | 57 | 0.000 |
Why?
| | Angina Pectoris | 1 | 1974 | 76 | 0.000 |
Why?
| | Postoperative Care | 1 | 1974 | 286 | 0.000 |
Why?
| | Arrhythmias, Cardiac | 1 | 1974 | 355 | 0.000 |
Why?
| | Anticoagulants | 1 | 1974 | 748 | 0.000 |
Why?
|
|
Greffe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|